A novel blood test analyzing fragments of cell-free DNA showed robust diagnostic performance for colorectal cancer across clinical subgroups, offering a promising noninvasive screening method.

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample ...

A groundbreaking study introduces new noninvasive screening tools that have the potential to greatly enhance patient comfort ...

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample ...

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...

Natera Inc., a cell-free DNA and precision medicine company, has acquired Foresight Diagnostics, a leader in ultrasensitive ...

An Arizona veteran who learned he has ALS is exploring a new blood test that researchers at UCLA are studying.

An Austin, Texas-based genetics-testing company that specializes in cell-free DNA and precision medicine has acquired Foresight Diagnostics Inc., a Boulder-based cancer-diagnostics company.

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample ...

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...

GC Genome, a leading clinical genomics and liquid biopsy company, announced that its study analyzing cell-free DNA (cfDNA) fragmentation patterns in 1,154 healthy individuals has been published in ...